All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubMDS HubMPN HubMultiple Myeloma

When is CAR-T a good option for patients with follicular and marginal zone lymphomas?

During the 4th European CAR T-cell Meeting, the Lymphoma Hub was pleased to speak with Gilles Salles, Memorial Sloane Kettering Cancer Center, New York, US. We asked, When is CAR-T a good option for patients with follicular and marginal zone lymphomas?

When is CAR-T a good option for patients with follicular and marginal zone lymphomas?

Salles begins by discussing studies in this area, such as ZUMA-5 and ELARA, highlighting high response and remission rates. However, Salles notes that we need more data on durability and the results of bi-specific antibodies compared with CAR-T. Salles concludes by predicting a promising future for therapies in indolent B-cell malignancies.

Share: